The Utility of Surveillance Bronchoscopy for the Detection of Subclinical Infection after Lung Transplantation  by Hanson, Kimberlv et al.
S14 Infections in Patients with Solid Organ Transplantation
BKVN is 8.3% the method is also cost-effective. Leflunomide treat-
ment seems to be effective for the clearance of BKVN.
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Six Month Incidence of Bloodstream Infections in Intestinal
Transplant Patients
Kauser Akhter, Cal Matsumoto, Thomas Fishbein, Stuart Kaufman,
Princy Kumar, Joseph Timpone. Georgetown University Hospital
Division of Infectious Disease, Washington, DC, USA
Background: Intestinal transplantation has emerged as a treat-
ment option for patients with life-threatening intestinal failure.
The most common complication and cause of death is infection.
Objective: To determine the 6 month post-operative incidence of
bloodstream infections (BSI), and to characterize associated risk
factors.
Material and Methods: We performed a retrospective chart review
of all small bowel transplant recipients between 2003 -2007. The
characteristics below were analyzed as potential risk factors for
BSI: colon/liver inclusion, total bilirubin >5, surgical complica-
tions, & acute rejection. Most patients received immunosuppres-
sion with basiliximab, tacrolimus, sirolimus and a prednisone taper.
6 patients received thymoglobulin instead of basiliximab.
Results: Fifty-six patients received an intestinal transplant from
November 2003 to July 2007. Twenty-three were adult (>18
years), and 33 pediatric. Nine adults and 25 children developed
BSI (p=0.006). Twenty-two patients received an isolated intesti-
nal transplant, 16 liver-intestine, 16 multivisceral, and 2 modi-
fied multivisceral. The patient characteristics are listed in table
1. Thirty-four of 56 patients (61%) had at least one episode of BSI.
A total of 85 episodes of BSI were observed, with 65.9% of BSI due
to Gram-positives, 34.1% Gram-negatives and 2.4% fungemia (table
2). The most common isolates were: VRE/non-VRE, Enterobacter,
Klebsiella and coagulase negative Staphylococci. The mean time to
first BSI was 26.4 days. Of 85 BSI episodes, 69 occurred in patients
who received a liver. In these 32 patients, 23 had BSI compared
to 11 of the 24 non-liver patients (p=0.048) (table 3). Of 27 pa-
tients with a total bilirubin >5mg/dL, 21 developed BSI compared
to 9 of the 29 patients with a total bilirubin ≤5mg/dL (p=0.000).
Severn of 11 colon inclusion patients developed BSI compared to
27/45 non-colon inclusion pts (p=ns). Of 21 patients with surgical
complications, 12 developed BSI versus 21 of the 35 patients with-
out complications (p=ns). Nineteen patients had acute rejection.
Twelve of these patients had BSI compared to 23 of the 37 patients
who did not reject (p=ns).
Table 1. Patient characteristics
Total number of patients 56
Adults / Pediatric 23 / 33
Males / Female 32 / 24
Average Age ± SD 18.4±19.8 yrs
Age range 6 months – 62 years
Colon inclusion 11 pts
Liver inclusion 32 pts
Surgical complications (perforation, leak, bleed, abscess) 21
Patients with acute rejection 19 pts
Abstract 30 – Table 2. Microbiology of BSI episodes
Organism Overall Colon +/– liver Non-colon +/– liver Liver
(n = 85 episodes) (n = 17 episodes) (n = 68 episodes) (n = 69 episodes)
Gram-positive cocci 56/85 12/17 44/68 49/69
(VRE, CNS, MRSA, MSSA, Strep viridans) (65.9%) (70.6%) (64.7%) (71.0%)
Gram-neg rods (Enterobacter, Klebsiella, 29/85 5/17 24/68 20/69
Pseudomonas, E .coli, Citrobacter, others**) (34.1%) (29.4%) (35.3%) (29.0%)
Candida species 2/85 1/17 1/68 2/69
(C. albicans, C. parapsilosis) (2.4%) (5.9%) (1.5%) (2.9%)
**Burkholderia, Stenotrophomonas, Serratia, Capnocytophaga.
Table 3. Patient variables and incidence of BSI
Variable Number of Number of p value
Pts Pts with BSI
Age (Pediatric vs. Adult) 33 / 23 25/9 0.006
Colon (Inclusion vs. No Inclusion) 11 / 45 7/27 ns
Liver (Inclusion vs. No Inclusion) 32 / 24 23/11 0.048
Total bilirubin at Tx (>5 vs ≤5) 27 / 29 21/9 0.000
Surgical complications (Present vs. Absent) 21 / 35 12/21 ns
Acute rejection (Present vs. Absent) 19 / 37 12/23 ns
Conclusions: BSI are a common complication of intestinal trans-
plant. The incidence appears to be higher in children. It appears
that liver inclusion and preoperative bilirubin >5 are associated
with a higher incidence of BSI. Acute rejection and colon inclusion
do not appear to have an influence on BSI incidence.
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The Utility of Surveillance Bronchoscopy for the Detection
of Subclinical Infection after Lung Transplantation
Kimberly Hanson, Sylvia Costa, Barbara Alexander. Duke
University Medical Center Departments of Medicine and
Pathology Durham, NC 27710 USA
Background: Surveillance bronchoscopy is often performed after
lung transplantation in an attempt to identify acute rejection or in-
fection before signs of disease develop. This practice is not known
to improve outcomes.
Objective: To evaluate the microbiologic yield of surveillance BAL
in lung transplant recipients during the first year post-transplant.
Methods: Medical records for all adults who underwent lung trans-
plantation at Duke University between 01 Jan 2005 and 01 Jan
2007 were reviewed. Surveillance bronchoscopies were performed
1, 3, 6 and 12 months after transplant. If acute rejection was de-
tected, the procedure was repeated monthly until 2 sequential
biopsies were negative. BAL specimens were classified according
to whether the subject had symptoms (i.e. new or worsening dysp-
nea, cough, sputum production, fever, a decrease in lung function,
or chest radiograph changes). The clinical relevance of microor-
ganisms detected by culture, direct fluorescent antibody [DFA] or
stain was determined and all therapeutic interventions recorded.
Results: During the study period 128 transplants (124 double-lung,
3 single-lung, and 1 heart-lung) were performed. The median
(range) subject age was 55 (17-70) years. The most common
conditions necessitating transplant were idiopathic pulmonary hy-
pertension (n=42), COPD (n=36), and cystic fibrosis (n=18). A total
of 630 surveillance BALs were submitted for microbiologic analysis;
28.7% (181/630) were from subjects with documented symptoms.
Most (67.5% [425/630]) surveillance samples grew only oropharyn-
geal flora and 4.9% (31/630) were completely negative. Overall,
27.9% (176/630) of specimens had a potential pathogen detected.
Of the potentially significant organisms identified, bacteria
accounted for 41.4% (72/174), fungi 21.8% (38/174), viruses 21.2%
(37/174), mycobacteria 7.5% (13/174), and PCP 1.1% (2/174).
Multiple pathogens were found in 14 samples. BAL fluid from symp-
tomatic subjects yielded a potential pathogen more often than
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samples from asymptomatic subjects (34.3% [62/181] vs. 25.4%
[114/449]; p=0.03). Potential pathogens in symptomatic subjects
were more likely to be treated than were pathogens in asymp-
tomatic subjects (83.9% [52/62] vs. 26.3% [30/114]; p<0.0001).
Conclusions: The majority of surveillance BAL cultures were non-
diagnostic and the results rarely altered the management of
asymptomatic lung transplant recipients. Routine mycobacterial
culture and PCP staining were of particularly low yield.
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Impact of Drug Interactions on Choice of Antifungal
Therapy in Treating IFI. A Case Report of Use of
Posaconazole to Treat Fusarium Soft Tissue Infection in a
Liver Transplant Patient on Sirolimus
Shariq Haider. McMaster University, Division of Infectious
Diseases, 3V42 1200 Main St West Hamilton Ontario Canada
Background: Fungal infections are the most common cause of cu-
taneous infections in solid organ transplant patients. We describe
a case of soft tissue infection of the toe caused by Fuasarium
chlamydosporum and Candida guilliermondii in a liver transplant
patient on sirolimus, and discuss the pharmacokinetic interactions
of sirolimus and the new triazoles and their impact on treatment
choices.
Case: A 57 year old male post liver transplant in 2005 for Budd
Chiari Syndrome on Sirolimus 2mg daily, cellcept 750mg po bid,
developed an invasive soft tissue infection of his 5th toe after
spending a few weeks at his cottage walking bare feet. He noted
marked swelling and purple discoloration of his 5th toe two weeks
after returning from his cottage in the summer of 2007 (Figure 1).
A biopsy of the toe was done and identified on culture Candida
guilliermondii and Fusarium chlamydosporum. Susceptibility test-
ing for both isolates was done (Table 1). Patient was treated with
posaconazole 400mg po bid for 6 months with complete resolu-
tion of infection. Sirolimus was dose adjusted to 1mg everyother
day due to significant incr. in AUC of Sirolimus through the CYP450
isoenzymes.
Figure 1
Table 1. Susceptibility profile
Candida guilliermondii
Fluconazole 2mg/L Susceptible
Itraconazole 0.25mg/L Susceptible
5-Flucytosine 0.03mg/L Susceptible
Amphotericin B 0.5 mg/L No interpretation
Voriconazole 0.12 mg/L
Caspofungin 0.25mg/L
Fusarium Chlamydosporum
Amphotericin B 0.5mg/L
Fluconazole 32 mg/L
Ketoconazole 1mg/L
Itraconazole 2mg/L
Voriconazole 0.5mg/L
Discussion: This case illustrates the benefits of new triazoles in
treating IFI, but highlights the drug interactions of the new tria-
zoles: voriconazole and posaconazole on treatment choices with a
review of the literature around these drug interactions.
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Respiratory Viral Infections in Renal Transplant Recipients
Mauro Jose Costa Salles1, Yvoty Alves dos Santos Sens2, Lucy
Villas Boas3, Clarisse Martins Machado3. 1Clinic of Infectious
Diseases, Department of Internal Medicine, Santa Casa de São
Paulo School of Medicine, São Paulo, Brazil; 2Nephrology,
Department of Internal Medicine, Santa Casa de São Paulo School
of Medicine, São Paulo, Brazil; 3Virology Laboratory, Institute of
Tropical Medicine, University of São Paulo (IMTSP-USP), São
Paulo, Brazil
Background: Solid organ transplant (SOT) recipients are partic-
ularly susceptible to community-acquired respiratory viruses and
they also appear more likely to experience pulmonary and extra-
pulmonary complications. Atypical clinical presentation caused by
influenza virus A and B or other virus are increasingly recognized
as a cause of morbidity including recipients rejection and chronic
allograft dysfunction.
Objectives: To determine the frequency and clinical aspects in-
cluding allograft complications of influenza A and B infection and
influenza-like illness caused by respiratory syncytial virus (RSV),
adenovirus, parainfluenza virus 1, 2 and 3 in renal transplant re-
cipients.
Methods: 434 nose-and-throat washes specimens were prospec-
tively collected from each patient every three weeks (5.78 samples
per patient) as well as clinical signs and symptoms of respiratory vi-
ral infections on 75 renal transplanted patients during six months.
Direct immunofluorescence (DIF) was the virological method used
for detecting respiratory virus.
Results: Influenza and flu-like symptoms were observed in 23.5%
of the subjects, including fever (temperature higher than 37.8°C),
nasal congestion, sore throat, cough, sneezing, headache, myal-
gia, weakness, fatigue and loss of appetite. Diagnosis of symp-
tomatic and asymptomatic patients with virus isolation collected
from nose-and-throat washes was able to detect only six episodes
of virus infection: 2 RSV, 2 parainfluenza, 1 influenza A and 1 in-
fluenza B. No significant difference was observed when serum cre-
atinine at six month was compared with baseline serum creatinine
(1.74±0.65, 1.84±0.55, p=0.312) and there were no serious com-
plications after virus infections during the six months period of
follow up.
Conclusion: Respiratory virus infections were not associated with
significant morbidity in renal transplant recipients.
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Characteristics of Transplant Recipients who Developed
Influenza in 2007-08 Despite Influenza Vaccination
Sherif Mossad. Department of Infectious Diseases, Cleveland
Clinic, Ohio, Cleveland, USA
Background: Influenza vaccination is less immunogenic in trans-
plant recipients than healthy people. Influenza A (H1N1) and B
circulating viruses during the 2007-2008 epidemic were different
from those contained in this season' s vaccine.
Objective: To describe clinical and immunological characteristics
of 15 transplant recipients who developed influenza despite in-
fluenza vaccination (group A), and compare them to 6 transplant
recipients who developed influenza in the absence of influenza
vaccination (group B), 13 transplant recipients who did not develop
